Drug Trial News

RSS

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Isis Pharmaceuticals, Inc. today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1 Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS).

11 Dec 2015

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).

10 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or "sIPV") candidate.

10 Dec 2015

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS (Safety and Efficacy ofNintedanib in Systemic SClerosIS) study.

10 Dec 2015

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

9 Dec 2015

Tetra begins human Phase 1 safety trials of BPN14770

Tetra Discovery Partners today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer's disease.

9 Dec 2015

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Rising Tide Foundation for Clinical Cancer Research, an international private foundation based in Switzerland, has awarded a US $800,000 grant to be released over two years for the ASCOLT study conducted by Dr John Chia, Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore.

9 Dec 2015

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.

9 Dec 2015

Novel antidepressant appears to be safe, effective against depression in clinical trial

A small clinical trial of a novel antidepressant that stimulates neurogenesis - the production of new brain cells - shows that the compound appears to be safe and may be effective against depression.

9 Dec 2015

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

8 Dec 2015

Paracetamol provides no benefits in fighting influenza virus

Some doctors may recommend that patients with the flu take acetaminophen, or paracetemol, to relieve their symptoms; however, a new randomized clinical trial found no benefits to the over-the-counter medication in terms of fighting the influenza virus or reducing patients' temperature or other symptoms.

8 Dec 2015

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult' treatment protocols, report Dana-Farber Cancer Institute scientists.

8 Dec 2015

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

Drug Trial News

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Lilly, Merck announce another immuno-oncology collaboration

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Tetra begins human Phase 1 safety trials of BPN14770

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Novel antidepressant appears to be safe, effective against depression in clinical trial

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Paracetamol provides no benefits in fighting influenza virus

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News